Related references
Note: Only part of the references are listed.Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Hussein Abdul-Hassan Tawbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis
Eliana Rulli et al.
CANCER (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1311OLong-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)
G V Long et al.
ANNALS OF ONCOLOGY (2019)
Immunotherapy of brain metastases: breaking a dogma
Anna Maria Di Giacomo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma
Marc C. Chamberlain et al.
NEURO-ONCOLOGY (2017)
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
Daniel N. Cagney et al.
NEURO-ONCOLOGY (2017)
Updates in the management of brain metastases
Nils D. Arvold et al.
NEURO-ONCOLOGY (2016)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study
MF Avril et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
